Bronchiectasis in an asymptomatic infant with cystic fibrosis diagnosed following newborn screening  by Mott, Lauren S. et al.
(2009) 285–287
www.elsevier.com/locate/jcfJournal of Cystic Fibrosis 8Bronchiectasis in an asymptomatic infant with cystic fibrosis diagnosed
following newborn screening
Lauren S. Mott a,b,c, Catherine L. Gangell a, Conor P. Murray d, Stephen M. Stick a,b,c,
Peter D. Sly a,b,⁎, on behalf of AREST CF a,b,c,d,e,f
a Division of Clinical Sciences, Telethon Institute for Child Health Research and Centre for Child Health Research, University of Western Australia, PO Box 855,
West Perth, WA, 6872, Australia
b Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, Australia
c School of Paediatrics and Child Health, University of Western Australia, Perth, Australia
d Department of Diagnostic Imaging, Princess Margaret Hospital for Children, Perth, Australia
e Murdoch Children's Research Institute, Melbourne, Australia
f Department of Respiratory Medicine, Royal Children's Hospital, Melbourne, Australia
Received 27 November 2008; received in revised form 16 April 2009; accepted 21 April 2009
Available online 15 May 2009Abstract
Many countries have introduced newborn screening for cystic fibrosis to facilitate diagnosis prior to the development of lung disease. Although
most infants with cystic fibrosis are asymptomatic from a respiratory point of view at diagnosis, structural lung disease has been detected by
computed tomography. We present a case of an asymptomatic infant with cystic fibrosis diagnosed following newborn screening who had
endobronchial infection with Pseudomonas aeruginosa and radiological evidence of bronchiectasis at 3 months of age.
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The introduction of newborn screening (NBS) programs to
detect cystic fibrosis (CF) came with the expectation that
diagnosis prior to the development of established disease would
improve disease outcomes. While growth and nutrition have
improved [1–3], no improvements in respiratory outcomes are
directly attributable to the introduction of NBS [1,3–5]. An
incorrect assumption that asymptomatic infants with CF do not
have lung disease may be the reason behind this lack of
improvement in respiratory outcomes resulting from earlier
diagnosis by NBS [6].⁎ Corresponding author. Division of Clinical Sciences, Telethon Institute for
Child Health Research, PO Box 855, West PerthWA 6872, Australia. Tel.: +61 8
9489 7814; fax: +61 8 9489 7700.
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doi:10.1016/j.jcf.2009.04.009Clinical symptoms and upper airway cultures provide the
guidance for many CF centres to direct further investigations
and treat presumed endobronchial infections. However, evi-
dence is accumulating that infection and inflammation occur
early in CF, and may occur in the absence of respiratory
symptoms [7]. Furthermore, upper airway cultures, including
oropharyngeal and nasopharyngeal suction specimens have
poor sensitivity in detecting endobronchial infections [8–11].
For these reasons, a view is emerging that routine early
surveillance programs based on regular bronchoalveolar lavage
(BAL) in infants and young children should represent the gold
standard for detecting endobronchial infection, even in patients
who have no respiratory symptoms [6]. Such surveillance
allows early detection of endobronchial infections and provides
an opportunity to eradicate pathogens prior to the development
of lung damage. To illustrate the potential importance of early
surveillance programs that include BAL, we present a case of and by Elsevier B.V. All rights reserved.
Fig. 1. Cross-sectional image from ultralow dose CT chest above the level of the
carina showing CT evidence of bronchiectasis in the right upper lobe (arrow).
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isolated from lower airways and bronchiectasis when investi-
gated soon after diagnosis following NBS.
2. Case report
A healthy infant diagnosed with CF following NBS
presented to our clinic. The infant was born at term following
a healthy pregnancy via an elective caesarean section. There
were no perinatal complications. Birth weight was 3.5 kg (50th
percentile) and length 50 cm (50th percentile). She was initially
well in the neonatal period and exclusively breastfed, but
developed profuse diarrhoea, with a 500 g loss of weight. After
commencing exclusive formula feeds at 1 week of age the
diarrhoea ceased, she regained weight and continued to thrive.
NBS was suggestive for CF with immunoreactive trypsin
elevated at 123 mcg/L (above 99th percentile, normal range
b70 mcg/L). Genotyping for common mutations found in
Western Australia detected a single Phe508del mutation of the
CF gene. A sweat test performed at 6 weeks of age was
diagnostic of CF (sweat chloride 94 mmol/L). Extended mutation
analysis revealed a class 1 mutation (Lys447ArgfsX2) in addition
to Phe508del. Faecal elastase indicated pancreatic insufficiency
(elastase 64 mcg/g faeces, normal range N200 mcg/g faeces).
The infant was referred to the Department of Respiratory
Medicine at Princess Margaret Hospital for Children, Australia,
at 6 weeks of age for routine care, consisting of parental
education, staphylococcal prophylaxis with amoxycillin clavu-
lanate, pancreatic enzyme replacement therapy, vitamin supple-
mentation (vitamins A complex, B complex, C, D, E, K, zinc
and folic acid), and sodium chloride supplementation.
As part of our routine clinical practice, we perform a
comprehensive clinical assessment soon after diagnosis,
including CT of the chest, bronchoscopy and BAL under
general anaesthesia. This review occurred at 3 months of age
when the infant was well with no clinically apparent lung
disease. No pathogens were isolated from an oropharyngeal
swab obtained immediately prior to the BAL. An ultra low dose
CT of the chest was obtained using a 3-slice techniqueperformed at end inspiration (25 cm H2O) and at end-expiration
(0 cm H2O), as previously described [12]. This showed
radiological evidence of mild bronchiectasis in the right upper
lobe, with the bronchial intraluminal diameter exceeding the
arterial diameter of the accompanying pulmonary artery (see
Fig. 1); gas trapping in the right upper, right lower and left lower
lobes; and widespread bronchial wall thickening throughout
both lungs. Bronchoscopy immediately following CT chest
showed white mucous sections in the lower third of the trachea
and some minor airway wall inflammation and oedema. BAL
specimens from the right middle lobe and left lingula both grew
a non-mucoid strain of P. aeruginosa at 105 colony forming
units per ml, with isolates sensitive to cefotaxime, ticarcillin and
clavulanate, tobramycin and ceftazidime.
We admitted this infant for P. aeruginosa eradication therapy,
according to routine clinical protocol, with 2weeks of intravenous
tobramycin (12 mg/kg daily) and intravenous ticarcillin clavula-
nate (100 mg/kg, TDS), followed by 4 weeks of nebulised
tobramycin (6 mg/kg BD) and oral ciprofloxacin (10 mg/kg BD).
Following discharge from hospital, the mother discontinued
ciprofloxacin as the infant disliked themedicine. By this stage, our
patient had developed a cough during chest physiotherapy. Repeat
BAL at 6 months of age demonstrated successful eradication of
P. aeruginosa. Again, oropharyngeal culture immediately prior to
bronchoscopy failed to detect P. aeruginosa. No change in infant
behaviour such as improvements in energy or appetitewas noticed
following eradication therapy.
3. Discussion
We present a case of a 3 month old infant with CF diagnosed
following NBS. Despite a lack of clinically apparent lung
disease, we detected endobronchial infection with
P. aeruginosa and demonstrated CT evidence of structural
lung disease, including bronchiectasis, at 3 months of age.
Inflammatory analysis of BAL fluid at the time of endobron-
chial infection demonstrated an increased inflammatory
response that improved following P. aeruginosa eradication,
with elevated proinflammatory cytokines and detectable
neutrophil elastase, indicating that the antiprotease defences
of the lung have been overwhelmed. The case illustrates that
asymptomatic infants with CF diagnosed following NBS can
have substantial lung disease that will only be detected by
comprehensive early surveillance programs that include both
CT scans and BAL.
NBS programs for CF have not clearly improved respiratory
outcomes. This may be attributable to lack of early detection of
lung disease and delayed initiation of treatment [6]. The view
that infants with CF have normal lungs at birth and that bacterial
infection initiates an exaggerated inflammatory response that
ultimately leads to lung tissue destruction is now being
questioned [13], with debate continuing as to whether an
intrinsic hyper-inflammatory state precedes infection in the CF
lung [8,14]. Pulmonary infections may be present soon after
birth in the absence of clinically significant lung disease [7], and
this case demonstrates that structural lung damage can also
occur in the absence of respiratory symptoms.
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endobronchial infections and successfully eradicate pathogens
prior to the development of irreversible lung damage. The
diagnosis of pulmonary infections in infancy is important, and
current surveillance techniques are not ideal. Our recent
experience, based on a comprehensive surveillance program,
confirms previous data that upper airway cultures are not
reliable in predicting endobronchial infection [8,9,11]. Rather,
BAL is the most reliable method for detecting endobronchial
infection in infants and young children with CF who are unable
to expectorate sputum [15].
Evidence based guidelines for the routine surveillance of
infants and young children with CF are currently lacking. The
techniques for detecting early endobronchial infection and lung
damage in infants and young children are readily available,
however these techniques are not routinely performed in all CF
clinics [6]. Through the research currently undertaken in early
disease surveillance programs as part of the AREST CF
collaboration, we hope to answer some of the questions about
the aetiology and progression of CF lung disease. In the
meantime, we suggest that CF centres should consider including
BAL programs for the early detection and eradication of
endobronchial infection. Furthermore, CT scans appear to
demonstrate significant lung disease in asymptomatic children
and should be considered as part of any comprehensive early
surveillance program.
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